New research has found an association between taking glucosamine, a popular over-the-counter supplement used for joint pain, and a higher likelihood of progressing from mild cognitive impairment to Alzheimer's disease. The ...
Jun 9, 2026
0
316
It might soon be "game over" for the video game controller. Yale researchers have developed a new kind of brain-computer interface (BCI) that lets humans play video games directly with their brains. Using real-time fMRI (functional ...
20 hours ago
0
156
Psilocybin is a naturally occurring psychoactive compound found in mushrooms of the Psilocybe genus. These mushrooms may have existed on Earth for nearly 65 million years, dating to the asteroid impact that caused the dinosaurs' ...
Even what many Americans consider moderate drinking is linked to an increased risk of death, disability, and chronic diseases such as cancer and heart disease, according to a new study in the Journal of Studies on Alcohol ...
Jun 9, 2026
0
95
As governments around the world struggle with ways to reverse plunging birth rates, new U.S. studies suggest they have ignored a key culprit—the smartphone.
Jun 9, 2026
0
38
Over the past few years, GLP-1 drugs have transformed the treatment landscape for obesity and type 2 diabetes. By mimicking a hormone that helps regulate blood sugar, slows digestion and curbs appetite, these medications ...
Researchers have identified a promising new therapeutic strategy for autism spectrum disorder (ASD). A research team led by Director KIM Eunjoon of the IBS Center for Synaptic Brain Dysfunctions has now identified a promising ...
Jun 9, 2026
0
27
Just 4 minutes of daily strengthening exercise dramatically increases key factors in quality of life for older adults, according to a new study led by researchers at Penn State College of Medicine. Results published in PLOS ...
20 hours ago
1
21
Eating when the body is normally asleep appears to desynchronize the circadian clocks of different cell types in the intestines, a UT Southwestern Medical Center study suggests. The findings, published in PNAS, could help ...
23 hours ago
0
10
The U.S. Food and Drug Administration has approved Shionogi's Xocova (ensitrelvir), an oral antiviral, for postexposure prophylaxis (PEP) of COVID‑19 in adults and adolescents aged 12 years and older.
Jun 9, 2026
0
10
